Sugi Predict

Sugi Predict / Targets / HIPK2

HIPK2

Homeodomain-interacting protein kinase 2 · Q9H2X6 · HIPK2 on Sugi Atlas →

33,250 patent compounds predicted against HIPK2, 21,442 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL741197 SCHEMBL741197 0.39 6/20
SCHEMBL443819 SCHEMBL443819 0.78 4/20
SCHEMBL147422 SCHEMBL147422 0.66 4/20
SCHEMBL857075 SCHEMBL857075 0.64 4/20
SCHEMBL422572 SCHEMBL422572 0.64 4/20
SCHEMBL419474 SCHEMBL419474 0.64 4/20
SCHEMBL144979 SCHEMBL144979 0.56 4/20
SCHEMBL415716 SCHEMBL415716 0.54 4/20
SCHEMBL410415 SCHEMBL410415 0.48 4/20
SCHEMBL458945 SCHEMBL458945 0.44 4/20
SCHEMBL734778 SCHEMBL734778 0.43 4/20
SCHEMBL857418 SCHEMBL857418 0.42 4/20
SCHEMBL742370 SCHEMBL742370 0.36 4/20
SCHEMBL422865 SCHEMBL422865 1.00 3/20
A-443654 A-443654 (SCHEMBL570604) 1.00 3/20
SCHEMBL423761 SCHEMBL423761 0.84 3/20
SCHEMBL424288 SCHEMBL424288 0.80 3/20
SCHEMBL419044 SCHEMBL419044 0.79 3/20
SCHEMBL424886 SCHEMBL424886 0.79 3/20
SCHEMBL422803 SCHEMBL422803 0.78 3/20

Clinical trials — most relevant to HIPK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Genetic Mechanisms and Additional Risk Factors Underlying Hip Dysplasia nanCOMPLETED
Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients nanCOMPLETED
Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs nanWITHDRAWN
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Use of miRNAs in Growth Hormone Deficiency (GHD) nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions nanRECRUITING
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Analysis of Intestinal Microflora Combined With DNA Methylation in Stool to Detect Colorectal Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HIPK2 binder may also engage these)

ProteinNameSimilarity
Q9QZR5 — 1.000 Q9QZR5 →
O88904 — 1.000 O88904 →
HIPK1 Homeodomain-interacting protein kinase 1 0.999 landscape →
Q9WUM7 — 0.997 Q9WUM7 →
A4L9P5 — 0.992 A4L9P5 →
HIPK3 Homeodomain-interacting protein kinase 3 0.991 landscape →
Q9ERH7 — 0.991 Q9ERH7 →
O88850 — 0.986 O88850 →
Q9WV30 — 0.984 Q9WV30 →
Q9H694 — 0.983 Q9H694 →
O88907 — 0.982 O88907 →
Q9HBD1 — 0.982 Q9HBD1 →
KDM6A Lysine-specific demethylase 6A 0.982 landscape →
Q6B4Z3 — 0.980 Q6B4Z3 →
Q64127 — 0.980 Q64127 →
Q7Z353 — 0.980 Q7Z353 →
Q5RJA1 — 0.979 Q5RJA1 →
Q8BJ34 — 0.978 Q8BJ34 →
Q9QWH1 — 0.978 Q9QWH1 →
A2A891 — 0.978 A2A891 →
Q9JIL5 — 0.978 Q9JIL5 →
O14607 — 0.977 O14607 →
Q93073 — 0.977 Q93073 →
O70546 — 0.977 O70546 →
Q8HWS3 — 0.977 Q8HWS3 →
D3ZGB1 — 0.977 D3ZGB1 →
P41157 — 0.977 P41157 →
Q8MQ70 — 0.977 Q8MQ70 →
Q5XJV7 — 0.977 Q5XJV7 →
Q5ZKW8 — 0.976 Q5ZKW8 →